FDA Approves Jemperli for Locally Advanced Rectal Cancer
GSK received U.S. FDA approval for Jemperli (dostarlimab) for adults with MSI-H/dMMR locally advanced rectal cancer.
Story updates
06:24:13 PM UTC
SquawkNews
AnaptysBio said GSK received FDA approval for Jemperli as the first and only immunotherapy for adults with stage II-III MSI-H/dMMR locally advanced rectal cancer, supported by AZUR-1 data and expedited review designations.Material DetailsContext by AI AnalystThis is a late-stage regulatory win buil…
SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. NASDAQ:ANAB, a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today announced that GSK has received U.S. Food and Drug Administration (FDA) approva…